Tag: CDK4/6 inhibitor

Ribociclib for HR+ Breast Cancer: Benefits, Risks & How It Works

Explore ribociclib, a CDK4/6 inhibitor for hormone receptor‑positive breast cancer, covering how it works, trial results, dosing, side effects, and practical patient tips.